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Abstract
Objective: Barlow disease is a still challenging pathology for heart surgeons. Aim of the present study is to report 5-year follow-up results of mitral valve repair in 
Barlow disease from a single large volume center. 
Methods: Between January 1st, 2008 and December 31st, 2011, 85 consecutive patients (54 men and 31 women) underwent mitral repair of Barlow mitral valve 
disease Mean age was 59 ±14 years (range: 28-85 years). Before surgery 47% of patients were in NYHA functional class III or IV. Reconstructive techniques were 
posterior leaflet quadrangular resection with (50.6%) or without (37.8%) leaflet sliding plasty, implantation of Gore-Tex artificial chordae (53.0%), and mitral 
annuloplasty, that was performed in all patients. Concomitant procedures included tricuspid valve repair, aortic valve repair or replacement, coronary artery bypass 
graft surgery, and modified maize procedure. 
Results: There were no perioperative in-hospital deaths. Intraoperative TEE did not disclose any early failure of valve repair. Postoperative minor complications 
were detected in 19 patients. Two patients died during follow-up. At five-year follow-up in the 83 surviving patients NYHA functional class improved significantly 
(p<0,0001). Significant postoperative atrial and ventricular remodeling occurred after surgery. 48 (57.8%) patients had no residual regurgitation and 24 (28.9%) 
showed trivial or mild mitral regurgitation. Mild to moderate regurgitation was found in 10 (12%), only one developed severe mitral regurgitation. Chordal elongation 
and anterior leaflet flail were related to recurrence of mitral regurgitation. 
Conclusion:  Repair of the mitral valve is currently the surgical treatment of choice for complex degenerative mitral valve disease and should be pursued even in 
the most advanced forms of Barlow disease. Careful selection of patients, early surgical intervention, optimization of surgical techniques including use of large 
size annuloplasty rings and artificial chordae, along with surgical expertise in mitral valve repair are the main determinants to decrease the risk of recurrent mitral 
regurgitation although progression of disease may be responsible for most of reinterventions. 
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Introduction 
Barlow disease is related to myxoid degeneration of all components 
of mitral valve apparatus [1]. The disease is defined according to the 
criteria described by Carpentier as: bileaflet prolapse > 2 mm; billowing 
valve with excess tissue and thickened leaflets ≥ 3 mm; severe anular 
dilatation [2]. Chordal elongation or rupture, anular and papillary 
muscle calcification may be present [2,3]. At present mitral valve repair 
is considered the surgical gold standard: repair is more frequently 
associated with reverse left ventricular remodeling and restoration 
of left ventricular function in comparison to valve replacement. 
Moreover, valve repair prevents prosthetic valve related complications. 
Previous investigations showed a decrease of peri operative mortality, 
increased long-term survival and freedom from re-intervention 
[4,5]. Due to anatomical complexity of the disease however surgical 
valve repair is usually performed only in near half of patients [6,7]. 
Guidelines encourage referral of patients with Barlow disease to 
centers with surgeons experienced in mitral valve repair in order to 
achieve to decrease the number of replaced valves [8-10]. The goals of 
reconstructive surgery are preservation or restoration of normal leaflet 
motion, creation of a large surface of coaptation, and stabilization of the 
entire annulus with a remodeling annuloplasty. Reconstructive surgery 
should be performed early in patients with severe mitral regurgitation 
(EROA ≥ 0.40 cm2) with reparable valves, before the occurrence of 
clinical symptoms, atrial fibrillation, pulmonary hypertension, and left 
ventricular dysfunction [11,12]. Present investigation reports 5-year 
follow-up results of mitral valve repair in 85 consecutive patients 
with Barlow disease underwent mitral valve repair at Heart surgery 
department of AOU Careggi. Factors related to late recurrence of 
mitral valve regurgitation were evaluated.  Materials and methods
Between January 1st, 2008 and December 31st, 2011, 85 consecutive 
patients (54 men and 31 women; mean age 59 ±14 years) with the 
features of Barlow disease underwent mitral valve repair at Heart 
Surgery Department of Azienda Ospedaliera Universitaria Careggi, 
Firenze. Barlow disease was diagnosed by preoperative echocardiogram 
and confirmed by surgical inspection. Patients presenting features of 
fibroelastic deficiency, Marfan disease and mild degenerative mitral 
valve prolapse were excluded from the study.
Transthoracic (TTE) and transesophageal echocardiography (TEE) 
were performed in all patients before surgery and the echocardiograms 
were reviewed by an expert cardiologist. Intraoperative TEE monitoring 
was performed during intervention in all cases. In table 1 are reported 
anatomic features of mitral valves. 
Surgical techniqueThe operation was performed through full 
sternotomy in 94.1%, whereas in 5 patients access was obtained with 
a minimally invasive approach. Mitral valve was accessed through a 
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patients had severe mitral valve regurgitation, the others (9.4%) 
moderate to severe. 
There were neither intraoperative nor postoperative in-hospital 
deaths. Intraoperative TEE did not disclose any early failure of valve 
repair. Postoperative minor complications were detected in 19 (22.4%) 
patients (Table 4): 2 patients (2.3%) underwent surgical revision for 
bleeding and 4 (4.7%) had pericardial effusion. In addition, 13 patients 
developed postoperative atrial fibrillation.
Transthoracic echocardiogram performed before discharge did not 
disclose more than trivial mitral regurgitation in 79 patients (92.9%) 
and none showed more than mild residual regurgitation. There was no 
evidence of SAM in any patient. At discharge 5 (5.9%) patients were in 
atrial fibrillation. 
Two patients died during follow-up; the first had a stroke 790 
day after surgery and the second died from a Parkinson’s disease 
complication 15 months after surgery. Six patients experienced new 
hospitalization for heart disease (2 patients for heart failure and 4 for 
AF). Freedom from endocarditis was 100% during follow-up. In Figure 
1 is shown event free survival during follow-up.
At the latest clinical examination, NYHA functional class improved 
significantly (χ2=23,32; p<0,0001): 73 (88.0%) patients were in class 
I and 10 (12.0%) patients in class II. Seventy-five (87.9%) patients 
were in sinus rhythm whereas 10 (12.1%) were treated with oral 
anticoagulation therapy for atrial fibrillation.
Transthoracic echocardiography (Table 5) showed a significant 
decrease of left ventricular diameters and volumes in comparison to 
preoperative data, suggesting a significant remodeling after surgery. A 
substantial decrease in left atrial size was also found (Table 5). 
At the end of follow-up 48 (57.8%) patients had no residual 
regurgitation and 24 (28.9%) showed trivial or mild mitral regurgitation. 
left atriotomy in the interatrial groove and the repair was performed 
according to the principles described by Carpentier and coll. [2,13,14]. 
Prolapse of the posterior leaflet was corrected in most cases by 
quadrangular resection, combined in 43 (50.6%) patients with a leaflet 
sliding plasty to reduce the risk of postoperative Systolic Anterior 
Motion (SAM) [14,15,16]. Mitral ring annuloplasty was performed 
in all patients. Mitral valve reconstruction was completed by cleft 
correction, when necessary. Associated procedures performed included 
tricuspid valve repair, aortic valve replacement, aortic valve repair, 
coronary artery bypass graft surgery, and a modified maze procedure. 
Operative details are reported in Table 2. Mean cross clamp (CCL) and 
Cardiopulmonary Bypass (CPB) times were 92.2 ± 32.7 minutes and 
114.6 ± 36.5 minutes, respectively.
Intraoperative transesophageal echocardiography was performed 
in all patient after weaning from cardiopulmonary bypass to detect any 
residual mitral regurgitation or the presence of left ventricular outflow 
tract obstruction. 
Follow-up
Patients were followed up periodically after surgery in an outpatient 
clinic with clinical assessment, Electrocardiogram and a trans-
thoracic echo (TTE). TTE examinations were performed by a single 
operator with a Sonos 5500 (Philips Medical System, Rotterdam, The 
Netherlands) ultrasound system. Mitral valve regurgitation was graded 
as none, mild, mild to moderate, moderate, moderate to severe and 
severe. Mean follow-up was 876 days (interquartile range: 192-1633 
days) and was closed on July 1st, 2011.
Statistical analysisStatistical analysis was performed using and 
SPSS 22.0 software (Chicago, IL, USA).Data are presented as mean ± 
standard deviation for continuous variable, as number and percentage 
for categorical variables, and as median [interquartile range] for non-
parametric variables. Unpaired Student’s t-test was used to determine 
differences between mean values for continuous variables. Pearson χ2 
test or Fisher’s exact tests were used to analyze baseline differences 
between categorical variables. Survival rate was estimated using Kaplan-
Meier curve. A p value < 0.05 was considered to indicate a significant 
difference. The role of each variable in predicting the outcome of 
surgical repair was estimated using logistic regression analysis. 
Results
Clinical and echocardiographic characteristics of patients include 
in the study are reported in Table 3. Forty- seven percent were in 
NYHA functional class III or IV before surgery. Seventy-seven (90.6%) 
Excess Tissue* 85  (100)
Bileaflet Prolapse* 85  (100)
Leaflet Thickening* 85  (100)
Anular Dilatation* 85  (100)
Anular Calcification 28  (33.0)
Chordae Elongation 31 (36.5)
Chordae Rupture 31  (36.5)
PM Elongation 1  (1.2)
PM Calcification 3  (3.5)
Multiple Clefts 7  (8.2)
Flail AML 8  (9.4)
Flail PML 32  (37.6)
Abbreviations: EROA: Effective Regurgitant Orifice Area; AP: Anterior-Posterior; PM: 
Papillary Muscle; AML: Anterior Mitral Leaflet; PML: Posterior Mitral Leaflet.
* Fundamental criteria to define Barlow’s Disease on surgical inspection.
Table 1. Anatomic features of mitral valves (n=85)
Mitral Valve Repair n  (%)
None 9  (10.6)
PMLQR 76  (89.4)
PMLTR 0  (0.0)
AMLTR 0  (0.0)
Sliding Plasty 43  (50.6)
Cleft Repair 7  (8.2)
Paracommissural E2E 2  (2.3)
Prostethic Ring 85  (100)
Ring type
CE 18  (21.2)
CEP 24  (28.2)
CEPII 31  (36.5)
Medtronic 11  (12.9)
Cosgrove 1  (1.2)
Ring size (mm) [range] 36.5±2.1 [32-40]
Artificial Chordae 45  (53.0)
AML 23  (27.1)
PML 5  (5.9)
AML + PML 17  (19.9)
Table 2. Operative data.
Abbreviations: PMLQR: Posterior Mitral Leaflet Quadrangular Resection; PMLTR: 
Posterior Mitral Leaflet Triangular Resection; AMLTR: Anterior Mitral Leaflet Triangular 
Resection; E2E: Edge To Edge; CE: Carpentier-Edwards Ring (Edwards Lifesciences, 
Irvine, CA); CEP: Carpentier Physio I Ring (Edwards Lifesciences, Irvine, CA); CEPII: 
Carpentier Physio II Ring (Edwards Lifesciences, Irvine, CA); AML: Anterior Mitral 
Leaflet; PML: Posterior Mitral Leaflet; CPB: Cardiopulmonary Bypass; CCL: (Aortic) 
Cross Clamp.
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Number of Patient 85
Age (years) [range] 59 ±14 [28-85]
Gender M/F 54/31 (63.5/36.5)
BSA (m2) [range] 1.84±0.20 [1.35-2.38]
Clinical Parametres n (%)
NYHA Class
I 27 (31.8)
II 18 (21.2)
III 30 (35.3)
IV 10 (11.7)
Atrial Fibrillation 27 (31.8)
Hypertension 27 (31.8)
Diabetes 1 (1.2)
COPD 2 (2.3)
Chronic Renal Disease 2  (2.3)
Redo 1 (1.2)
Echocardiographic Parametres
EDD (mm) 58.02±6.14 [40-73]
ESD (mm) 34.81±6.88 [21-60]
ST (mm) 10.32±1.42 [7-14]
WT (mm) 10.04±1.27 [7-14]
EDV (ml) 152.40±43.91 [52-287]
ESV (ml) 55.84±19.54 [15-132]
EDVI (ml/m2) 82.30±19.36 [31.5-138]
ESVI (ml/m2) 30.26±9.36 [9-71]
LVEF  (%) 62.32±7.11 [45-76]
LAD M-mode (mm) 47.95±6.47 [36-67]
LA Area (cm2) 28.50±7.46 [17-50]
PAP mean (mmHg) 37.08±15.88 [20-120]
Vena Contracta (cm) 0.74±0.16 [0.3-1.1]
EROA (cm2) 0.58±0.26 [0.25-1.6]
Anulus AP (mm) 43.05±3.92 [33-55]
Abbreviations: M/F: Male/Female; BSA: Body Surface Area; NYHA: New York Heart 
Association; COPD: Chronic Obstructive Pulmonary Disease; EDD: End-Diastolic 
Diameter; ESD: End-Systolic Diameter; ST: Septum Thickness; WT: Wall Thickness; 
EDV: End-Diastolic Volume; ESV: End-Systolic Volume; EDVI: End-Diastolic Volume 
Index; ESVI: End-Systolic Volume Index; LVEF: Left Ventricular Ejection Fraction; 
LAD: Left Atrium Diameter; LA: Left Atrium; PAP: Pulmonary Artery Pressure.
Table 3. Clinical and echocardiographic characteristics 
Preoperative 
Data
Follow-up Data t  P
LVEF 
(%)
   62.32±7.11 58.50±5.87 3.80 0.0002
EDD 
(mm)
58.02±6.14 51.52±5.18 7.35 <0.0001
ESD 
(mm)
34.81±6.88 31.25±4.77 3.87 0.002
EDV 
(ml)
152.40±43.91 131.10±38.77 3.31 0.0011
ESV 
(ml)
55.84±19.54 55.64±21.30 0.04 n.s.
EDVI (ml/m2) 82.30±19.36 70.88±18.32 3.89 0.0001
ESVI (ml/m2) 30.26±9.36 30.05±10.27 0.90 n.s.
LAD M-mode 
(mm)
47.95±6.47 40.95±5.87 7.26 <0.0001
LA Area (cm2) 28.50±7.46 19.28±4.04 9.81 <0.0001
Abbreviations: LVEF: Left Ventricular Ejection Fraction; EDD: End-Diastolic Diameter; 
ESD: End-Systolic Diameter; EDV: End-Diastolic Volume; ESV: End-Systolic Volume; 
EDVI: End-Diastolic Volume Index; ESVI: End-Systolic Volume Index; LAD: Left 
Atrium Diameter; LA: Left Atrium.
Table 5. Comparison between preoperative and follow-up echocardiographic data.
Mitral valve lesion Group 1 (n=11) Group 2 ( n=72) p
Anular Calcification 4  (36.4%) 20 (27%) 0.74
Chordae Elongation 7  (63%) 24 (33%) 0.0166
Chordae Rupture 8  (72.7%) 24(33%) 0.0163
Flail AML 4  (36.4%) 4  (6%) 0.0096
Flail PML 6  (54.5%) 26 (36%) 0.188
Abbreviations: AML: Anterior Mitral Leaflet; PML: Posterior Mitral Leaflet.
Table 6. Univariate analysis, Fisher Exact Test. 
None 66  (77.7)
Revision for Bleeding 2  (2.3)
Post-operative SAM 0  (0.0)
Drainage for Pericardial Effusion 4  (4.7)
Post-operative AF Onset 13  (15.3)
Table 4. Early Complications.
Abbreviations: SAM: Systolic Anterior Motion, AF: Atrial Fibrillation.
Moderate regurgitation was found in 10 (12%), only one developed 
severe mitral regurgitation (Figure 2). Mean transvalvular gradient was 
2.67 ± 0.88 mmHg (range:1.2-5 mmHg). 
Recurrent mitral regurgitation was more frequent in patients with 
chordal elongation or rupture and with anterior leaflet flail (Table 
6). Patients with recurrent mitral regurgitation were older (mean age 
66.8 ± 13.0 years vs. to 58.1 ± 12.6) and had a larger preoperative left 
ventricular end-diastolic diameter (62.4 ± 4.9 mm vs. 57.2 ± 5.1 mm 
p=0.009) and end-diastolic volume index (93.9 ± 18.8 ml/m2 vs. 80.1 ± 
18.9 ml/m2, p=0.03). The effect of association of specific surgical repair 
techniques and of other associated surgical procedures performed on 
mid-term and long-term results did not show any relation with clinical 
outcome. 
Discussion
Mitral valve repair is the technique of choice to correct MV 
regurgitation due to Barlow disease with excellent results in reference 
centers with large activity volumes [18]. A systematic, standardized 
approach including intraoperative TEE is fundamental to achieve 
a qualitative evaluation of anatomic changes of mitral valve in order 
to plan surgical strategy. Results from present investigation suggest 
that mitral valve repair in Barlow disease is associated with low 
operatory risk and low incidence of perioperative complications. Long 
term related mortality is negligible while a significant left atrial and 
ventricular remodeling and functional improvement has been found 
at 5-year follow-up. About 13% of patients showed moderate to severe 
Figure 1. Event free survival after mitral valve repair
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recurrent mitral regurgitation at last echocardiographic examination, 
none required re-intervention. Chordal elongation or rupture and 
anterior leaflet flail were associated with recurrent mitral regurgitation. 
A similar incidence of recurrent mitral valve regurgitation was 
reported by Flameng at al [19]. In 348 patients that underwent 
mitral valve  repair  for degenerative  valve  incompetence, they found 
at 5 years a 17.8% recurrence rate of  mitral regurgitation (>2/4). 
Recurrence rate was higher in patients with  Barlow  disease  than in 
patients with fibroelastic deficiency. Factors related to recurrence of 
MV regurgitation were performing chordal shortening, the nonuse of 
sliding plasty and the nonuse of an annuloplasty ring.
Gillinov et al. [20] demonstrated that late failure presents two 
hazard phases: an early peaking phase in the first year followed by a 
slow-rising late risk phase. Surgical techniques may be more frequently 
responsible for early recurrence while valve-related factors leading to 
recurrent regurgitation from chordal rupture or elongation may be 
related to late recurrence. It is well recognized that the process of tissue 
degeneration, involving mainly the chordae, goes on after surgical 
correction.
A new pathology was found in 80 (55%) patients who needed 
surgical re-intervention for recurrent mitral regurgitation [21] . 
Failure of the initial repair was found in 61 (42%) patients. The mitral 
valve was re-repaired in 64 (44%) patients and replaced in 81 (56%) 
patients. Mitral re-repair was performed in almost half of patients and 
was associated with better functional results and longer survival. Other 
authors reported that mitral valve disease progression was the main 
cause of repair failure, in particular in presence of AML flail valve [22]. 
The implantation of artificial chordae probably can prevent, at some 
extent, the progress of the disease; we used artificial chordae in more 
than a half of cases, and this proportion is increasing in more recent 
experience. 
Conclusion
Repair of the mitral valve is currently the best surgical option for 
complex degenerative mitral valve disease and should be pursued 
even in the most advanced forms of Barlow disease. Careful selection 
of patients, early surgical intervention, optimization of surgical 
techniques including use of large size annuloplasty rings and artificial 
chordae, along with surgical expertise in mitral valve repair are the 
main determinants to reduce the risk of recurrent mitral regurgitation 
and to ensure a better outcome.
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